



## OPEN ACCESS

## APPROVED BY

Giuseppe Remuzzi,  
Istituto di Ricerche Farmacologiche Mario Negri  
IRCCS, Italy

## \*CORRESPONDENCE

Frontiers Editorial Office,  
✉ [research.integrity@frontiersin.org](mailto:research.integrity@frontiersin.org)

RECEIVED 18 November 2024

ACCEPTED 25 November 2024

PUBLISHED 05 December 2024

## CITATION

Frontiers Editorial Office (2024) Retraction:  
CXCL6 promotes renal interstitial fibrosis in  
diabetic nephropathy by activating JAK/  
STAT3 signaling pathway.  
*Front. Pharmacol.* 15:1530358.  
doi: 10.3389/fphar.2024.1530358

## COPYRIGHT

© 2024 Frontiers Editorial Office. This is an  
open-access article distributed under the terms  
of the [Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in  
other forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in this  
journal is cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway

Frontiers Editorial Office\*

## A Retraction of the Original Research Article

### [CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway](#)

by Sun M-Y, Wang S-J, Li X-Q, Shen Y-L, Lu J-R, Tian X-H, Rahman K, Zhang L-J, Nian H and Zhang H (2019). *Front. Pharmacol.* 10:224. doi: [10.3389/fphar.2019.00224](https://doi.org/10.3389/fphar.2019.00224)

The journal retracts the 25 March 2019 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication concerns were identified in Figure 6C. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.